title: Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy.
abstract: Multi-targeted tyrosine kinase inhibitors (TKIs) have played an increasingly important role in the treatment of non-small cell lung cancer (NSCLC). Many recently published phase III trials have shown bittersweet efficacies of these drugs. How to optimize the efficacies of TKIs has been a hot topic in the era of individualized therapy. In this article, we review the up-to-dated advances in research on the application of TKIs for NSCLC treatment.
authors: Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
authors: Caicun
authors: C
authors: Zhou
keywords: Lung cancer; crizotinib; multi-targeted drugs; sorafenib; sunitinib; vandetanib